Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
Recruiting · NCT06926595 · Registry updated 2026-04-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention | Hemic and Lymphatic Diseases, Neoplasms by Site, graft versus host disease, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, neoplasm | Recruiting | Phase 2 | 2026-04-03 | NCT06926595 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Milton S. Hershey Medical Center | 79 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Penn State Cancer Institute | Hershey | United States | 17 |